AbbVie $ABBV
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS136
PHASE 3 / 2-374
RECRUITING61
READOUTS ≤12 MONTHS37
READOUT SLIPPED >6 MO46%
Delay Index: of 105 active trials registered more than a year ago, 48 have moved their primary completion (readout) date by more than 6 months since first registration (median +4.0 months). See all sponsors →
Open AbbVie on the live radar map → 📅 $ABBV readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SELECT-COMPARE NCT02629159 |
P3 | Active, not recruiting | Rheumatoid Arthritis | 1629 | 2017-10-27 (+3 mo) |
| KEEPsAKE2 NCT03671148 |
P3 | Active, not recruiting | Psoriatic Arthritis (PsA) | 444 | 2020-06-22 (-7 mo) |
| KEEPsAKE 1 NCT03675308 |
P3 | Active, not recruiting | Psoriatic Arthritis | 964 | 2020-10-08 (-3 mo) |
| AD Up NCT03568318 |
P3 | Active, not recruiting | Atopic Dermatitis | 1533 | 2021-02-16 (+14 mo) |
| Viale-a NCT02993523 |
P3 | Active, not recruiting | Acute Myeloid Leukemia (AML) | 443 | 2021-12-01 (+22 mo) |
| IMGN632 NCT03386513 |
P1/2 | Active, not recruiting | Blastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm | 179 | 2024-10-02 (+50 mo) |
| TRANSFORM-2 NCT04468984 |
P3 | Active, not recruiting | Myelofibrosis (MF) | 330 | 2025-01-29 (+35 mo) |
| TNB-383B NCT03933735 |
P1/2 | Active, not recruiting | Multiple Myeloma | 220 | 2026-05 (+62 mo) |
| ATO MM NCT06806293 |
P3 | Active, not recruiting | Menstrual Migraine (MM) | 468 | 2026-06-29 (-8 mo) |
| Telisotuzumab vedotin NCT03539536 |
P2 | Active, not recruiting | Non-small Cell Lung Cancer | 270 | 2026-07 (+56 mo) |
| Mirvetuximab Soravtansine NCT06682988 |
P2 | Recruiting | Advanced High-Grade Epithelial Ovarian Cancer; Primary Peritoneal Cancer | 110 | 2026-07 (-21 mo) |
| Pomalidomide NCT03539744 |
P3 | Active, not recruiting | Multiple Myeloma | 265 | 2026-08 (+67 mo) |
| Adalimumab NCT06100744 |
P3 | Recruiting | Juvenile Psoriatic Arthritis | 40 | 2026-09 |
| ASCENT NCT05407636 |
P3 | Active, not recruiting | AMD; nAMD | 735 | 2026-10 (+30 mo) |
| AGN-151586 NCT07730554 |
P2 | Active, not recruiting | Forehead Lines | 84 | 2026-10 |
| AAVIATE NCT04514653 |
P2 | Active, not recruiting | Neovascular Age-Related Macular Degeneration (nAMD) | 146 | 2026-10-13 (+68 mo) |
| ABBV-932 NCT06846320 |
P2 | Recruiting | Generalized Anxiety Disorder (GAD) | 315 | 2026-11 |
| Mirvetuximab soravtansine NCT05456685 |
P2 | Active, not recruiting | High Grade Ovarian Cancer; Primary Peritoneal Cancer | 125 | 2026-11 (+28 mo) |
| LIVIGNO-1 NCT05822752 |
P2 | Active, not recruiting | Hepatocellular Carcinoma | 130 | 2026-11 (-2 mo) |
| ReVenG NCT04895436 |
P2 | Recruiting | Chronic Lymphocytic Leukemia (CLL) | 75 | 2026-11 (+27 mo) |
| Switch-Up NCT06389136 |
P3 | Active, not recruiting | Atopic Dermatitis | 184 | 2026-11 (+14 mo) |
| Intrepid NCT06468228 |
P3 | Active, not recruiting | Hidradenitis Suppurativa | 1400 | 2026-12 |
| ATMOSPHERE NCT04704921 |
P2/3 | Active, not recruiting | AMD; nAMD | 671 | 2026-12 (+45 mo) |
| ABBV-400 NCT06107413 |
P2 | Active, not recruiting | Unresectable Metastatic Colorectal Cancer | 280 | 2026-12 (+2 mo) |
| Start Up Japan NCT06701331 |
P3 | Active, not recruiting | Atopic Dermatitis | 99 | 2027-01 |
| LIVIGNO-2 NCT06109272 |
P2/3 | Active, not recruiting | Hepatocellular Carcinoma | 89 | 2027-01 (-42 mo) |
| Lutikizumab NCT06972446 |
P2 | Recruiting | Rheumatoid Arthritis | 180 | 2027-02 |
| Mirvetuximab Soravtansine NCT06365853 |
P2 | Active, not recruiting | Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive | 108 | 2027-02 (+8 mo) |
| Lutikizumab NCT06524635 |
P2 | Recruiting | Hidradenitis Suppurativa; Atopic Dermatitis | 60 | 2027-02 |
| Azacitidine NCT04086264 |
P1/2 | Active, not recruiting | Acute Myeloid Leukemia | 218 | 2027-02 (+56 mo) |
| AURORA NCT06602479 |
P2 | Active, not recruiting | Migraine | 309 | 2027-02 (+5 mo) |
| SELECT-SLE NCT05843643 |
P3 | Active, not recruiting | Systemic Lupus Erythematosus | 1014 | 2027-03 (+5 mo) |
| LIVIGNO-3 NCT06632951 |
P2 | Active, not recruiting | Urothelial Carcinoma | 150 | 2027-03 (-17 mo) |
| ABBV-932 NCT07220460 |
P2 | Active, not recruiting | Bipolar I or II Disorder | 84 | 2027-03 (-1 mo) |
| 3112 Ped BPD NCT04777357 |
P3 | Recruiting | Depression; Bipolar I Disorder | 380 | 2027-03 (+37 mo) |
| AFFIRM NCT06063967 |
P3 | Active, not recruiting | Crohn's Disease | 289 | 2027-03 (+11 mo) |
| GLORIOSA NCT05445778 |
P3 | Active, not recruiting | Ovarian Cancer; Peritoneal Cancer | 520 | 2027-04 (+1 mo) |
| EMBARK NCT06718101 |
P2 | Active, not recruiting | Atopic Dermatitis | 83 | 2027-05 |
| Ubro Peds NCT05125302 |
P3 | Recruiting | Migraine | 1059 | 2027-05 (+15 mo) |
| Carfilzomib NCT02899052 |
P2 | Active, not recruiting | Multiple Myeloma | 120 | 2027-06 (+87 mo) |
| U-ACTIVATE NCT03006068 |
P3 | Active, not recruiting | Ulcerative Colitis (UC) | 950 | 2027-07 (+6 mo) |
| Verona NCT04401748 |
P3 | Active, not recruiting | Myelodysplastic Syndrome (MDS) | 531 | 2027-07 (+29 mo) |
| ELARIS EM-COC NCT04333576 |
P3 | Active, not recruiting | Endometriosis | 800 | 2027-07 (+34 mo) |
| Telisotuzumab Adizutecan NCT06614192 |
P2 | Active, not recruiting | Metastatic Colorectal Cancer | 74 | 2027-08 (-20 mo) |
| REVAMP NCT06880744 |
P3 | Active, not recruiting | Ulcerative Colitis | 573 | 2027-08 (-13 mo) |
| Venetoclax NCT03844048 |
P3 | Active, not recruiting | Chronic Lymphocytic Leukemia; Acute Myeloid Leukemia | 165 | 2027-08 (+31 mo) |
| U-ENDURE NCT03345823 |
P3 | Active, not recruiting | Crohn's Disease | 747 | 2027-09 (+103 mo) |
| Lutikizumab NCT06257875 |
P2 | Active, not recruiting | Ulcerative Colitis | 156 | 2027-09 (+4 mo) |
| Armour Thyroid NCT06345339 |
P2/3 | Active, not recruiting | Hypothyroidism | 2701 | 2027-09 (-9 mo) |
| Icalcaprant NCT07276997 |
P2 | Recruiting | Major Depressive Disorder | 195 | 2027-09 |
| Telisotuzumab Adizutecan NCT06772623 |
P1/2 | Recruiting | Non Small Cell Lung Carcinoma; c-MET | 252 | 2027-11 |
| UBRO MM NCT06417775 |
P3 | Active, not recruiting | Migraine | 496 | 2027-11 (+2 mo) |
| Icalcaprant NCT06696755 |
P2 | Recruiting | Bipolar I Disorder; Bipolar II Disorder | 195 | 2027-11 (+12 mo) |
| CERVINO NCT06158841 |
P3 | Active, not recruiting | Multiple Myeloma | 421 | 2027-12 |
| Lutikizumab NCT05139602 |
P2 | Active, not recruiting | Hidradenitis Suppurativa | 210 | 2027-12 (+49 mo) |
| UBRO PEDS OLE NCT05127954 |
P3 | Enrolling by invitation | Migraine | 1200 | 2028-01 (+8 mo) |
| IMGN151 NCT07024784 |
P2 | Recruiting | Gynecologic Cancers; Platinum-Sensitive Ovarian Cancer | 377 | 2028-01 |
| SEQUENCE NCT04524611 |
P3 | Active, not recruiting | Crohn's Disease (CD) | 527 | 2028-02 (+59 mo) |
| Emraclidine NCT07145918 |
P2 | Recruiting | Schizophrenia | 268 | 2028-02 |
| ABBV-383 (Etentamig) NCT06158854 |
P1/2 | Recruiting | Immunoglobulin Light Chain (AL) Amyloidosis | 76 | 2028-02 (+26 mo) |
| NOA HYDRATION NCT07880756 |
P3 | Recruiting | Skin Quality | 150 | 2028-02 |
| Telisotuzumab Vedotin NCT06568939 |
P2 | Recruiting | Non-Small Cell Lung Cancer; c-MET | 150 | 2028-02 |
| Venetoclax NCT06428019 |
P3 | Recruiting | Chronic Lymphocytic Leukemia | 170 | 2028-03 (+16 mo) |
| Viti-Up NCT06118411 |
P3 | Active, not recruiting | Vitiligo | 614 | 2028-03 (+28 mo) |
| ABBV-295 NCT07752979 |
P2 | Recruiting | Obesity; Overweight | 360 | 2028-03 |
| Atogepant NCT05711394 |
P3 | Recruiting | Episodic Migraine | 450 | 2028-03 |
| AndroMETa-CRC NCT06820463 |
P2 | Recruiting | Metastatic Colorectal Cancer | 390 | 2028-03 |
| OptIMMize-2 NCT04862286 |
P3 | Active, not recruiting | Psoriasis | 132 | 2028-04 (-20 mo) |
| TrenibotulinumtoxinE and OnabotulinumtoxinA NCT07871513 |
P2 | Recruiting | Upper Facial Lines; Glabellar Lines | 300 | 2028-06 |
| NAAVIGATE NCT07592273 |
P2/3 | Recruiting | Diabetic Retinopathy | 576 | 2028-06 |
| Venetoclax NCT07387471 |
P2 | Active, not recruiting | Waldenstrom Macroglobulinemia; Lymphoplasmacytic Lymphoma | 14 | 2028-07 |
| U-ASTOUND NCT05782907 |
P3 | Active, not recruiting | Ulcerative Colitis | 122 | 2028-08 |
| Step-Up HS NCT05889182 |
P3 | Active, not recruiting | Hidradenitis Suppurativa | 1328 | 2028-08 (+33 mo) |
| NOA LIFT NCT07794878 |
P3 | Recruiting | Nasolabial Folds | 288 | 2028-08 |
| SELECT-TAK NCT04161898 |
P3 | Active, not recruiting | Takayasu Arteritis (TAK) | 56 | 2028-08 (+73 mo) |
| COMMAND NCT03398135 |
P3 | Active, not recruiting | Ulcerative Colitis (UC) | 1242 | 2028-09 (+73 mo) |
| AGN-151607-DP NCT07226791 |
P2 | Recruiting | Ventral Hernia | 200 | 2028-09 |
| Telisotuzumab Adizutecan NCT07769502 |
P2 | Recruiting | Pancreatobiliary Cancers; Pancreatic Ductal Adenocarcinoma | 168 | 2028-09 |
| XEN63 Glaucoma Treatment System NCT06822738 |
P3 | Recruiting | Primary Open Angle Glaucoma | 130 | 2028-11 |
| AGN-151607-DP NCT07673107 |
P2 | Recruiting | Upper Limb Essential Tremor | 94 | 2028-11 |
| RGX-314 SRLTFU NCT03999801 |
P2 | Enrolling by invitation | Neovascular Age-related Macular Degeneration; Wet Macular Degeneration | 865 | 2028-12 |
| Telisotuzumab Vedotin NCT04928846 |
P3 | Recruiting | Non Small Cell Lung Cancer; c-MET | 768 | 2028-12 (+21 mo) |
| Risankizumab NCT07933536 |
P2 | Not yet recruiting | Moderate to Severe Psoriasis | 105 | 2028-12 |
| FLORENZA NCT07059845 |
P2 | Recruiting | Ovarian Cancer | 400 | 2029-01 |
| FORTIFY NCT03105102 |
P3 | Active, not recruiting | Crohn's Disease | 1336 | 2029-02 (+106 mo) |
| Jump Up AA JP NCT07023302 |
P3 | Active, not recruiting | Alopecia Areata | 125 | 2029-02 |
| RISE NCT05995353 |
P3 | Recruiting | Crohn's Disease | 110 | 2029-04 |
| AGN-193408 SR NCT04499248 |
P1/2 | Active, not recruiting | Open-angle Glaucoma; Ocular Hypertension | 100 | 2029-04 (+59 mo) |
| SEZanne NCT07155174 |
P2 | Recruiting | Small Cell Lung Cancer | 180 | 2029-04 (-29 mo) |
| AndroMETa-CRC NCT07525206 |
P3 | Recruiting | Colorectal Cancer | 990 | 2029-05 |
| SELECT-sJIA NCT05609630 |
P3 | Recruiting | Juvenile Idiopathic Arthritis | 90 | 2029-06 (+32 mo) |
| NOA VOLUME NCT06734351 |
P3 | Recruiting | Mid Face Volume Deficit | 231 | 2029-07 (+9 mo) |
| ABBV-722 NCT07904754 |
P2 | Not yet recruiting | Rheumatoid Arthritis | 250 | 2029-07 |
| Lutikizumab NCT06865105 |
P2 | Recruiting | Psoriatic Arthritis | 300 | 2029-08 (+19 mo) |
| ABBV-142 NCT07230288 |
P2 | Recruiting | Idiopathic Pulmonary Fibrosis | 165 | 2029-09 |
| ABBV-6628 NCT07160179 |
P1/2 | Recruiting | Geographic Atrophy; Age-Related Macular Degeneration | 66 | 2029-10 |
| Telisotuzumab Adizutecan NCT07744126 |
P2 | Recruiting | Head and Neck Squamous Cell Carcinoma | 150 | 2029-10 |
| Telisotuzumab Adizutecan NCT07023289 |
P2 | Recruiting | Colorectal Cancer | 140 | 2029-11 |
| ELAPR002f Injectable Gel NCT07207369 |
P3 | Recruiting | Acne Scars | 395 | 2029-11 |
| Start Up NCT06461897 |
P3 | Active, not recruiting | Atopic Dermatitis | 699 | 2029-11 (+26 mo) |
| ABBV-1480 NCT07756645 |
P3 | Recruiting | Non-Small Cell Lung Cancer | 940 | 2029-12 |
| Target CD NCT06548542 |
P2 | Recruiting | Crohn's Disease | 590 | 2030-01 (+25 mo) |
| Carboplatin NCT06890338 |
P2 | Recruiting | Epithelial Ovarian Cancer; Fallopian Tube Cancer | 140 | 2030-02 (+4 mo) |
| Telisotuzumab Adizutecan NCT07821684 |
P3 | Not yet recruiting | Non-Squamous Non-Small Cell Lung Cancer | 660 | 2030-03 |
| Up-AA NCT06012240 |
P3 | Recruiting | Alopecia Areata | 1500 | 2030-04 (+58 mo) |
| ABBV-706 NCT07365241 |
P3 | Recruiting | Small Cell Lung Cancer | 531 | 2030-09 |
| Telisotuzumab Adizutecan NCT07155187 |
P2/3 | Recruiting | Non-Small Cell Lung Cancer; c-MET | 490 | 2030-09 (-11 mo) |
| ABBV-1758 NCT07599670 |
P1/2 | Recruiting | Alzheimer's Disease | 210 | 2030-10 |
| AndroMETa-GEA NCT06628310 |
P2 | Active, not recruiting | Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | 185 | 2030-10 |
| Surzetoclax NCT06953960 |
P1/2 | Recruiting | Multiple Myeloma | 325 | 2030-12 |
| Telisotuzumab Adizutecan NCT07196644 |
P2 | Recruiting | Solid Tumors Harboring MET Amplification | 100 | 2030-12 |
| Venetoclax NCT02966756 |
P2 | Active, not recruiting | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | 66 | 2030-12 |
| U-EMPOWER NCT06332534 |
P3 | Active, not recruiting | Crohn's Disease | 111 | 2031-01 (-15 mo) |
| ARTIA Reconstructive Tissue Matrix NCT06575192 |
P3 | Recruiting | Breast Reconstruction | 264 | 2031-02 (+14 mo) |
| Atogepant NCT06810505 |
P3 | Recruiting | Chronic Migraine | 420 | 2031-03 |
| Dexamethasone NCT03314181 |
P2 | Active, not recruiting | Multiple Myeloma | 156 | 2031-05 |
| Standard of Care NCT05296447 |
P2 | Active, not recruiting | Diabetic Retinopathy, DR | 103 | 2031-06 (+40 mo) |
| Telisotuzumab adizutecan NCT07490301 |
P2/3 | Recruiting | Metastatic Pancreatic Ductal Adenocarcinoma; PDAC | 900 | 2031-06 |
| Standard of Care NCT05210803 |
P2 | Enrolling by invitation | Neovascular Age-Related Macular Degeneration (nAMD) | 116 | 2031-07 (+54 mo) |
| ABBV-706 NCT07895056 |
P2 | Not yet recruiting | Extensive Stage-Small Cell Lung Cancer | 80 | 2031-08 |
| Risankizumab NCT07697456 |
P2 | Recruiting | Crohn's Disease; Ulcerative Colitis | 2000 | 2031-10 |
| LIVIGNO-4 NCT06236438 |
P2/3 | Active, not recruiting | Non-Small Cell Lung Cancer | 167 | 2031-10 |
| Alveltamig NCT07895043 |
P2 | Not yet recruiting | Extensive Stage-Small Cell Lung Cancer (ES-SCLC) | 80 | 2031-12 |
| Upadacitinib NCT07772492 |
P3 | Recruiting | Severe Alopecia Areata | 300 | 2032-03 |
| Kaleidoscope NCT05707949 |
P3 | Enrolling by invitation | Migraine Prophylaxis | 650 | 2032-04 (+33 mo) |
| REVIVAL NCT07581002 |
P2/3 | Recruiting | Acute Myeloid Leukemia | 660 | 2032-06 |
| Ph3 Peds Viti NCT07896434 |
P3 | Not yet recruiting | Non-Segmental Vitiligo | 154 | 2032-08 |
| 25mg Eluxadoline NCT04880876 |
P3 | Enrolling by invitation | Irritable Bowel Syndrome | 124 | 2032-12 (+60 mo) |
| Etentamig NCT07728188 |
P3 | Recruiting | Relapsed or Refractory Multiple Myeloma | 520 | 2033-02 |
| Surabgene Lomparvovec (ABBV-RGX-314) NCT07007065 |
P3 | Recruiting | Neovascular Age-related Macular Degeneration | 561 | 2033-03 |
| MIGHTY NCT07071519 |
P3 | Recruiting | Ulcerative Colitis | 120 | 2034-07 |
| Etentamig NCT07793422 |
P3 | Not yet recruiting | Amyloid Light Chain (AL) Amyloidosis | 370 | 2034-12 |
| ABBV-722 NCT07933211 |
P2/3 | Not yet recruiting | Systemic Sclerosis | 580 | 2035-06 |
| Etentamig NCT06892522 |
P1/2 | Recruiting | Multiple Myeloma | 602 | 2035-12 (-3 mo) |
| Standard of Care NCT07005102 |
P2/3 | Recruiting | Non-Squamous Non-Small Cell Lung Cancer; c-MET | 854 | 2036-11 (+59 mo) |
| Etentamig NCT07095452 |
P2/3 | Recruiting | Multiple Myeloma | 680 | 2041-03 (-10 mo) |